Year: 2023

Not for distribution to U.S. newswire services or dissemination in the United States VANCOUVER, British Columbia, Dec. 01, 2023 (GLOBE NEWSWIRE) — HydroGraph Clean Power Inc. (CSE: ‎HG) (OTCQB: HGCPF) (the “Company” or “HydroGraph”) is pleased to announce that the Company has completed the first tranche of its non-brokered private placement (the “Offering”) previously announced on October 30, 2023. Pursuant to the first tranche of the Offering, the Company issued an aggregate of 10,260,856 units of the Company (the “Units”) for aggregate gross proceeds of approximately C$1.03 million. The Units were offered in US dollars and Canadian dollars at the respective prices of US$0.074 and C$0.10. The majority of the proceeds were provided by new US-based subscribers but also included an investment by Gulf Cryo, LLC, a major industrial...

TORONTO, Dec. 01, 2023 (GLOBE NEWSWIRE) — Platinex Inc. (CSE: PTX) (OTCQB: PANXF, Frankfurt: 9PX) (“Platinex” or the “Company”) is pleased to announce that the Company has increased its previously announced flow through financing (see press release dated Nov 27, 2023) to $1,500,000 (“the FT Offering”). The flow through common shares are priced at C$0.04 per share (“FT common share”). Each FT common share consists of one common share of the Company. The closing of this final tranche of the FT Offering is underway and is expected to be completed shortly. The Company will use the gross proceeds of the FT Offering to incur eligible Canadian exploration expenses that are “flow-through critical mineral mining expenditures” and will qualify as flow-through mining expenditure as such terms are defined in the Income Tax Act (Canada) related...

Posters with new preclinical data on the pharmacokinetic and pharmacodynamic behavior of OV329 support its profile as a potential best-in-class GABA aminotransferase inhibitor Disease models provide further evidence characterizing OV350 and its anticipated seizure reduction and neuroprotective profile, including its ability to reverse diazepam-resistant seizuresNEW YORK, Dec. 01, 2023 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that five posters featuring data supporting its OV329 and OV350 programs for the potential treatment of epilepsies and treatment-resistant seizures will be presented at the 2023 American Epilepsy Society (AES) Annual Meeting...

Figure 1https://brixtonmetals.com/wp-content/uploads/2023/11/Figure-1_1Dec2023.jpegFigure 2https://brixtonmetals.com/wp-content/uploads/2023/11/Figure-2_1Dec2023.jpegFigure 3https://brixtonmetals.com/wp-content/uploads/2023/11/Figure-3_1Dec2023-scaled.jpgFigure 4https://brixtonmetals.com/wp-content/uploads/2023/11/image.pngFigure 5https://brixtonmetals.com/wp-content/uploads/2023/11/Figure-5_1Dec2023.jpegVANCOUVER, British Columbia, Dec. 01, 2023 (GLOBE NEWSWIRE) — Brixton Metals Corporation (TSX-V: BBB, OTCQB: BBBXF) (the “Company” or “Brixton”) is pleased to announce the final batch of 2023 drill results from the Trapper Gold Target at its wholly owned Thorn Project. The project is located in Northwest British Columbia, 90km east of Juneau, Alaska and within the Taku River Tlingit...

Also Announces December 2023 and Q1/2024 Dividends TORONTO, Dec. 01, 2023 (GLOBE NEWSWIRE) — Firm Capital Mortgage Investment Corporation (the “Corporation“) (TSX: FC) is pleased to announce: (i) 2023 Special Dividend; (ii) December 2023 Dividend; and (iii) Q1/2024 Dividends. SPECIAL DIVIDEND – 4.2% INCREASE OVER 2022 TOTAL DIVIDENDSThe Corporation is pleased to announce an estimated 2023 special year-end cash dividend (the “Special Dividend”) on its outstanding common shares of $0.054 per share. This special dividend represents a significant increase over the $0.014 per share special dividend declared and paid at the end of 2022. Overall, for 2023, the Corporation will have declared and paid total dividends of $0.99 per share, which is a 4.2% increase over the $0.95 per share declared and paid for 2022. The precise...

MONTREAL, Dec. 01, 2023 (GLOBE NEWSWIRE) — Goodfood Market Corp. (“Goodfood” or “the Company”) (TSX: FOOD), a leading Canadian online meal solutions company, today reached an agreement for an extension of its credit facility with Desjardins Capital Markets and Investissement Québec. The facility will now provide bank financing totalling approximately $5 million consisting of a $2.1 million term loan, a $1.3 million revolving credit facility, and $1.4 million in additional short-term financing. The facility comes to maturity in November 2024. Goodfood intends to use the facilities mainly for working capital, general corporate purposes and capital expenditures. “We are pleased to have worked closely with our lending group and to extend credit facilities that continue to support our efforts to grow our profitability and cash flows....

AC Immune appoints Madiha Derouazi as CSODr. Madiha Derouazi appointed as new CSO of AC ImmuneAC Immune appoints Christopher Roberts as CFOChristopher Roberts confirmed in CFO role on a permanent basisAC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFOOutstanding scientist and entrepreneur Dr. Madiha Derouazi appointed as new CSO Retiring CSO Dr. Marie Kosco-Vilbois will remain as consultant to ensure smooth handover Christopher Roberts, Interim Chief Financial Officer, confirmed in role on a permanent basisLausanne, Switzerland, December 1, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the appointment, as of January 1st, 2024, of Dr. Madiha Derouazi as Chief...

PARSIPPANY, N.J., Dec. 01, 2023 (GLOBE NEWSWIRE) — Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company, today issued the following statement regarding the U.S. Food and Drug Administration (FDA) Safety Communication on evaluation of certain plastic syringes: “embecta, the world’s largest manufacturer of plastic insulin syringes, manufactures all of our syringes distributed worldwide at our facility in Holdrege, Nebraska,” said Shaun Curtis, SVP, Global Manufacturing & Supply Chain. “The safety notice issued by the FDA on November 30, 2023, only applies to plastic syringes made in China, and therefore has no impact on the ongoing production or sale of any embecta syringe products.” “In the coming year, embecta will mark 100 years since our predecessors developed the world’s first syringe dedicated to insulin...